Weakness in Marinus Pharmaceuticals (MRNS) a Buying Opportunity - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Joon Lee said today's weakness in Marinus Pharmaceuticals (NASDAQ: MRNS) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE